Ironwood Pharmaceuticals Announces Participation in J.P. Morgan Biotech CEO/CFO Conference Call

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will participate in the J.P. Morgan Biotech: CEO/CFO Conference Call Series at 10:00 a.m. Eastern Time on Friday, May 28, 2010.

Conference call details are as follows:

  • Live conference call (U.S.): (888) 889-1309
  • Live conference call (outside the U.S.): (773) 756-0161
  • Live passcode: BIOTECH
  • Replay (U.S.): (866) 501-0089
  • Replay (outside the U.S.): (203) 369-1817
  • Replay passcode: 2597

A recording of the call will be available for telephone replay for one week following the call.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (NASDAQ: IRWD) is an entrepreneurial pharmaceutical company dedicated to the art and science of great drugmaking. Linaclotide, Ironwood's GC-C agonist, is being evaluated in a confirmatory Phase 3 program for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation. Ironwood also has a growing pipeline of additional drug candidates in earlier stages of development. Ironwood is located in Cambridge, Mass.



CONTACT:

Ironwood Pharmaceuticals
Susan Brady, 617-621-8304
Corporate Communications
[email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.